EN DE
Watch Cantourage Group SE for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cantourage Group SE (HIGH) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Cantourage Group SE stock €4.78, price €5.34, that is 10.5% below the price, quality 49 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare DE

CG Cantourage Group SE logo Thin data Nov 10, 2026

Cantourage Group SE

HIGH · XETRA
Expensive, weak quality

Our calculation puts a fair price 10% below what the stock costs today.

Quality 49/100
Mixed Growth (revenue 3y +254.3 %/yr in EUR)
Thin margins · 3.2% net margin (TTM)
Fair value €4.78 · Overvalued
Trails peers (3/9)
Narrow moat 25/100 · thin data
Thin data
Estimate
Watch Cantourage Group SE for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€19.20 €2.39 Fair Value €4.78 Nov 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

48‑month range €2.39 – €19.20 · fair‑value band €3.59 – €5.98 · the €5.34 price screens above the €4.78 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Cantourage Group in your weekly email

Every Wednesday you see whether Cantourage Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cantourage Group SE operates as a medical cannabis company in Europe and internationally. The company offers cannabis flowers, extracts, dronabinol, tetrahydrocannabinol, and cannabidiol products. It exports its products.

Show moreShow less

The company distributes its products through pharmacies, wholesalers, and partners. Cantourage Group SE was founded in 2019 and is headquartered in Berlin, Germany.

Stock analysis

Cantourage Group SE (HIGH) currently trades at €5.34, while our estimate is €4.78, 10% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: €3.59 (bear) to €5.98 (bull), the price of €5.34 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Cantourage Group SE reported revenue of €23.6M in FY2023 versus €530K in FY2020, a compound +254.3%/yr. Reported net income was −€4.3M in FY2023.

Key figures

Market cap €66.6M Micro · P/S ratio 16.0 · EPS (TTM) €−0.5200 · Net margin 3.2% · Return on equity 0.3% · Return on assets (EBIT) −15.6% (4-year average) · Operating margin 4.6% · Revenue growth (YoY) +173%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).

What moves the price

The share trades about 19% below its 52-week high and 123% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −10%, HIGH screens cheaper than that median.

Fair Value

Bear €3.59 Fair Value €4.78 Bull €5.98
Price €5.34 · Downside -10.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 13
How much profit the company makes from its sales and capital
Quality Growth 40
Are margins and returns getting better?
Financial strength 77
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 59
How calm the share price moves, does not count
Price momentum 55
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 85
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 56/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−110.7% (2020) → −18.4% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed

HIGH screens overvalued: fair value 10% below the price. Compare with Merck KGaA →

Compare Cantourage Group SE with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside −10.5% · Above median
Profitability
Return on equity (12 months) 0.3% · Below median
Return on assets −9.7% · Bottom 25%
Net margin (12 months) 3.2% · Below median
Operating margin (12 months) 4.6% · Below median
Growth and dividend
Revenue growth (quarter YoY) 172.6% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.67× · Cheaper than median
P/S (12 months) 17.04× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)19 · sector 18
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)1 · sector 25
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs HIGH
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs HIGH
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs HIGH
Haleon plc HLN $9.06 $8.62 −5% vs HIGH
Merck KGaA MRK €149.35 €109.18 −27% vs HIGH
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs HIGH
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs HIGH
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs HIGH
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs HIGH
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs HIGH

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cantourage Group SE: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cantourage Group SE Fair Value". https://www.fairvalue-calculator.com/stock/HIGH

Frequently asked questions

Is Cantourage Group SE (HIGH) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is €4.78 versus a price of €5.34, about 10% lower (overvalued).
What is the fair value of HIGH?
Our estimate for Cantourage Group SE is €4.78 (as of Nov 10, 2026), built from audited fundamentals. The current price: €5.34.
What is the quality score of HIGH?
Cantourage Group SE has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cantourage Group SE (HIGH)?
Our calculated price target is the estimate of €4.78 (as of Nov 10, 2026). Cautious scenario €3.59, optimistic scenario €5.98. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Cantourage Group SE stock forecast for 2026?
Our estimate puts fair value at €4.78, about 10% lower versus a price of €5.34 (overvalued). Cautious scenario €3.59, optimistic scenario €5.98. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Cantourage Group SE (HIGH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cantourage Group SE it is €4.78 per share (as of Nov 10, 2026), against a price of €5.34.
Is Cantourage Group SE stock overvalued or undervalued in 2026?
As of Nov 10, 2026, HIGH trades above its calculated fair value: price €5.34, fair value €4.78, a gap of about −10% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HIGH?
No. The price is what the market pays today (€5.34); the fair value is what the company's own numbers justify (€4.78). For Cantourage Group SE the two are €0.5600 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cantourage Group SE worth?
The market values Cantourage Group SE at about €66.6M (market capitalisation, as of Nov 10, 2026). Per share that is €5.34; our models calculate a fair value of €4.78 per share.
What do the bullish and bearish scenarios say about HIGH?
Our models span a range for Cantourage Group SE: cautious scenario €3.59, base €4.78, optimistic €5.98 per share (as of Nov 10, 2026, price €5.34). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cantourage Group SE (HIGH)?
Balance-sheet figures for Cantourage Group SE (as of Nov 10, 2026): return on equity 0.3%. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is HIGH from its 52-week high?
Cantourage Group SE trades at €5.34, about 19% below its 52-week high of €6.56 and 123% above the low of €2.39 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of €4.78 is for.
Which stocks are comparable to Cantourage Group SE?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cantourage Group SE stock attractive at the current price?
The data as of Nov 10, 2026: price €5.34, calculated fair value €4.78 (−10%), Quality Score 49/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Cantourage Group SE itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cantourage Group SE (HIGH)?
The closing price on Nov 10, 2026 was €5.34. Our estimate is €4.78, about 10% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cantourage Group SE right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Cantourage Group SE

How large is the market capitalisation of Cantourage Group SE (HIGH)?
The market capitalisation of Cantourage Group SE is €66.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cantourage Group SE (HIGH)?
The price-to-sales ratio of Cantourage Group SE is 16.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cantourage Group SE (HIGH)?
Earnings per share at Cantourage Group SE are €−0.5200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cantourage Group SE (HIGH)?
The net margin of Cantourage Group SE is 3.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cantourage Group SE (HIGH)?
The return on equity (ROE) of Cantourage Group SE is 0.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cantourage Group SE (HIGH)?
On an EBIT basis the return on assets of Cantourage Group SE is −15.6% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cantourage Group SE (HIGH)?
The operating margin of Cantourage Group SE is 4.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cantourage Group SE (HIGH)?
Revenue at Cantourage Group SE is growing +173% versus a year earlier (3y avg +254%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed

Watch Cantourage Group SE in the live analysis

One click puts Cantourage Group SE on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.